As Indiana farmers move deeper into planting season, crop disease experts at Purdue University are urging growers to take ...
The core of NIH’s AI push is to break down data silos that limit how quickly researchers can respond to emerging public ...
Techcyte, developer of the Fusion unified digital pathology platform, and Biobase, creator of an agentic data discovery platform for connecting multi-modal clinical data to pharma and research buyers, ...
In addition to the shares sold in the initial public offering described above, Odyssey announced a concurrent sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, ...
March 2026 saw the US Food and Drug Administration grant breakthrough device designation to Path Assist Derm, an artificial ...
Researchers hoped results from the latest trial on low-dose lithium would settle the question of lithium’s potential to ...
Roche RHHBY said Wednesday it will acquire U.S.-based digital pathology and AI company PathAI in a deal worth up to $1.05 ...
PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...
The agreement could generate an additional $300 million for PathAI if the it leads to the achievement of certain milestones.
Roche (RHHBY) stock rises 1.55% following announcement of PathAI acquisition for $750M, enhancing AI-powered cancer ...
Lovell Government Services and GraMedica Partner to Expand Federal Access to HyProCure® for Veterans, Military, and ...
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results